ES3010483T3 - Compositions for treating ineffective erythropoiesis - Google Patents
Compositions for treating ineffective erythropoiesis Download PDFInfo
- Publication number
- ES3010483T3 ES3010483T3 ES21153891T ES21153891T ES3010483T3 ES 3010483 T3 ES3010483 T3 ES 3010483T3 ES 21153891 T ES21153891 T ES 21153891T ES 21153891 T ES21153891 T ES 21153891T ES 3010483 T3 ES3010483 T3 ES 3010483T3
- Authority
- ES
- Spain
- Prior art keywords
- actriib
- gdf trap
- polypeptide
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547932P | 2011-10-17 | 2011-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3010483T3 true ES3010483T3 (en) | 2025-04-03 |
Family
ID=48141315
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21153891T Active ES3010483T3 (en) | 2011-10-17 | 2012-10-17 | Compositions for treating ineffective erythropoiesis |
| ES19161424T Active ES2869168T3 (es) | 2011-10-17 | 2012-10-17 | Composiciones para tratar la mielofibrosis |
| ES12842601T Active ES2741477T3 (es) | 2011-10-17 | 2012-10-17 | Composiciones para tratar la sobrecarga de hierro en talasemia |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19161424T Active ES2869168T3 (es) | 2011-10-17 | 2012-10-17 | Composiciones para tratar la mielofibrosis |
| ES12842601T Active ES2741477T3 (es) | 2011-10-17 | 2012-10-17 | Composiciones para tratar la sobrecarga de hierro en talasemia |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20130243743A1 (enExample) |
| EP (3) | EP2797620B1 (enExample) |
| JP (4) | JP6092883B2 (enExample) |
| KR (4) | KR20140084211A (enExample) |
| CN (3) | CN107837390A (enExample) |
| AU (4) | AU2012326207B2 (enExample) |
| BR (3) | BR122019023174B1 (enExample) |
| CA (1) | CA2852683A1 (enExample) |
| DK (2) | DK3520805T3 (enExample) |
| EA (2) | EA034563B1 (enExample) |
| ES (3) | ES3010483T3 (enExample) |
| HK (2) | HK1250341A1 (enExample) |
| WO (1) | WO2013059347A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3489257A1 (en) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| EP2781222B1 (en) | 2005-11-23 | 2017-08-02 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2677007A1 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP2481415B1 (en) | 2007-02-09 | 2019-09-11 | Acceleron Pharma Inc. | Pharmaceutical compositions comprising Activin-ActRIIA antagonists |
| JP2010539236A (ja) | 2007-09-18 | 2010-12-16 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TWI626945B (zh) | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| JP5912078B2 (ja) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ， インコーポレイテッド | 熱発生性脂肪細胞を増加させるための方法 |
| EP3290439B1 (en) | 2009-06-12 | 2020-09-02 | Acceleron Pharma Inc. | Truncated actriib-fc fusion proteins |
| JP6211767B2 (ja) * | 2009-09-09 | 2017-10-11 | アクセルロン ファーマ， インコーポレイテッド | ＡｃｔＲＩＩｂアンタゴニストならびにその投薬および使用 |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| KR20130132824A (ko) | 2010-11-08 | 2013-12-05 | 악셀레론 파마 인코포레이티드 | Actriia 결합제 및 이의 용도 |
| WO2013055476A1 (en) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| EP3119418B1 (en) * | 2014-03-21 | 2022-02-23 | Acceleron Pharma Inc. | Composition for use in a method of treating or preventing anemia by inhibiting activin b and gdf11 |
| BR112016024319B1 (pt) * | 2014-04-18 | 2024-01-23 | Acceleron Pharma Inc | USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME |
| MA40008A (fr) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| TWI730949B (zh) * | 2014-12-03 | 2021-06-21 | 美商西建公司 | 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途 |
| SI3286206T1 (sl) | 2015-04-22 | 2021-07-30 | Biogen Ma Inc. | Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase |
| JP6976859B2 (ja) * | 2015-05-13 | 2021-12-08 | セルジーン コーポレイション | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
| EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| EP3370754B1 (en) * | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| HUE067225T2 (hu) | 2016-07-27 | 2024-10-28 | Acceleron Pharma Inc | Mielofibrózis kezelésére szolgáló készítmények |
| KR102761094B1 (ko) | 2016-10-05 | 2025-02-03 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CN119241685A (zh) | 2016-11-10 | 2025-01-03 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| HUE068733T2 (hu) | 2017-06-14 | 2025-01-28 | Celgene Corp | Eljárások mieloproliferatív neoplazma-asszociált mielofibrózis anémia kezelésére |
| CN111801112A (zh) | 2017-11-09 | 2020-10-20 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
| KR20200109330A (ko) | 2018-01-12 | 2020-09-22 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법 |
| WO2019217715A1 (en) | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| CA3176735A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| US5354934A (en) * | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| NZ502795A (en) | 1995-04-11 | 2001-09-28 | Gen Hospital Corp | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
| US5807839A (en) * | 1997-04-15 | 1998-09-15 | Advanced Viral Research Corp. | Method for stimulating red blood cell production |
| NZ513642A (en) | 1999-01-21 | 2004-02-27 | Metamorphix Inc | Growth differentiation factor inhibitors and uses therefor |
| US7842691B2 (en) * | 2002-10-15 | 2010-11-30 | Celgene Corporation | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide |
| EP3489257A1 (en) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TWI626945B (zh) * | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| CN102655872B (zh) * | 2009-08-13 | 2016-01-20 | 阿塞勒隆制药公司 | Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平 |
-
2012
- 2012-10-17 KR KR1020147013325A patent/KR20140084211A/ko not_active Ceased
- 2012-10-17 EA EA201490809A patent/EA034563B1/ru not_active IP Right Cessation
- 2012-10-17 CN CN201711069431.3A patent/CN107837390A/zh active Pending
- 2012-10-17 DK DK19161424.7T patent/DK3520805T3/da active
- 2012-10-17 AU AU2012326207A patent/AU2012326207B2/en active Active
- 2012-10-17 CA CA2852683A patent/CA2852683A1/en active Pending
- 2012-10-17 WO PCT/US2012/060650 patent/WO2013059347A1/en not_active Ceased
- 2012-10-17 KR KR1020207004201A patent/KR20200019261A/ko not_active Ceased
- 2012-10-17 EP EP12842601.2A patent/EP2797620B1/en active Active
- 2012-10-17 KR KR1020197025484A patent/KR102079482B1/ko active Active
- 2012-10-17 EP EP21153891.3A patent/EP3875104B1/en active Active
- 2012-10-17 ES ES21153891T patent/ES3010483T3/es active Active
- 2012-10-17 DK DK21153891.3T patent/DK3875104T3/da active
- 2012-10-17 EA EA202090053A patent/EA202090053A3/ru unknown
- 2012-10-17 BR BR122019023174-5A patent/BR122019023174B1/pt active IP Right Grant
- 2012-10-17 CN CN201711069457.8A patent/CN107693776A/zh active Pending
- 2012-10-17 US US13/654,191 patent/US20130243743A1/en not_active Abandoned
- 2012-10-17 BR BR112014009528-0A patent/BR112014009528B1/pt active IP Right Grant
- 2012-10-17 CN CN201280061672.2A patent/CN103987403B/zh active Active
- 2012-10-17 BR BR122019023166-4A patent/BR122019023166B1/pt active IP Right Grant
- 2012-10-17 KR KR1020227017193A patent/KR20220075438A/ko not_active Ceased
- 2012-10-17 ES ES19161424T patent/ES2869168T3/es active Active
- 2012-10-17 EP EP19161424.7A patent/EP3520805B1/en active Active
- 2012-10-17 JP JP2014537186A patent/JP6092883B2/ja active Active
- 2012-10-17 ES ES12842601T patent/ES2741477T3/es active Active
-
2017
- 2017-01-23 US US15/413,184 patent/US20170137791A1/en not_active Abandoned
- 2017-02-09 JP JP2017022176A patent/JP6383821B2/ja active Active
- 2017-03-08 AU AU2017201580A patent/AU2017201580B2/en active Active
- 2017-07-28 US US15/663,361 patent/US20170327800A1/en not_active Abandoned
-
2018
- 2018-07-30 HK HK18109792.1A patent/HK1250341A1/zh unknown
- 2018-08-06 JP JP2018147507A patent/JP6796626B2/ja active Active
- 2018-09-26 HK HK18112295.7A patent/HK1252940A1/zh unknown
- 2018-10-11 AU AU2018247262A patent/AU2018247262B2/en active Active
-
2020
- 2020-08-07 US US16/987,756 patent/US20210207107A1/en active Pending
- 2020-08-24 JP JP2020140889A patent/JP2020186277A/ja active Pending
- 2020-12-09 AU AU2020286229A patent/AU2020286229A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018247262B2 (en) | Methods and compositions for treating ineffective erythropoiesis | |
| US10889626B2 (en) | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels | |
| ES2796121T3 (es) | Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos | |
| ES2808139T3 (es) | Trampas de GDF | |
| AU2017204230B2 (en) | Use of GDF traps to increase red blood cell levels | |
| AU2019204127A1 (en) | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels | |
| EA043601B1 (ru) | Способы и композиции для лечения неэффективного эритропоэза |